The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 163:488-493, March 2006
doi: 10.1176/appi.ajp.163.3.488
© 2006 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Artaloytia, J. F.
* Articles by Palomo, T.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Artaloytia, J. F.
* Articles by Palomo, T.
Related Collections
* Neurotransmitters
* Atypical Neuroleptics
* Schizophrenia Spectrum Disorders
* Symptoms/Dimensions
* Other Neuroimaging

Negative Signs and Symptoms Secondary to Antipsychotics: A Double-Blind, Randomized Trial of a Single Dose of Placebo, Haloperidol, and Risperidone in Healthy Volunteers

Juan Francisco Artaloytia, M.D., Celso Arango, M.D., Adrienne Lahti, M.D., Javier Sanz, M.D., Ana Pascual, M.D., Pedro Cubero, M.D., David Prieto, M.Sc., and Tomás Palomo, M.D.

OBJECTIVE: Despite the clinical observation that antipsychotics can produce negative symptoms, no previous controlled study, to our knowledge, has evaluated this action in healthy subjects. The present study assessed observer-rated and self-rated negative symptoms produced by conventional and second-generation antipsychotics in healthy volunteers. METHOD: The authors used a double-blind, placebo-controlled trial of single doses of haloperidol (5 mg) and risperidone (2.5 mg) in normal subjects. Thirty-two subjects were administered haloperidol, risperidone, and placebo in a random order. Motor variables and observer-rated negative symptoms were assessed after 3–4 hours and subjective negative symptoms and drowsiness after 24 hours. RESULTS: Neither of the active drugs caused significant motor extrapyramidal symptoms after administration. Haloperidol caused significantly more negative signs and symptoms than placebo on the Scale for the Assessment of Negative Symptoms (SANS) and two self-rated negative symptom scales: the Subjective Deficit Syndrome Scale total score and an analog scale that evaluates subjective negative symptoms. Risperidone caused significantly more negative signs and symptoms than placebo on the Brief Psychiatric Rating Scale (BPRS), the SANS, the Subjective Deficit Syndrome Scale total score, and the analog scale for subjective negative symptoms. After control for drowsiness, risperidone but not haloperidol produced more negative symptoms than placebo on the BPRS and the SANS. Significance was lost for the subjective negative symptoms with both drugs. CONCLUSIONS: Single doses of both haloperidol and risperidone produce negative symptoms in normal individuals. Drowsiness may be an important confounding factor in the assessment of negative symptoms in antipsychotic trials.




This article has been cited by other articles:


Home page
Psychiatr. Serv.Home page
D. C. Owens
What CATIE Did: Some Thoughts on Implications Deep and Wide
Psychiatr Serv, May 1, 2008; 59(5): 530 - 533.
[Abstract] [Full Text] [PDF]


Home page
Adv. Psychiatr. Treat.Home page
D. C. Owens
How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia
Advan. Psychiatr. Treat., January 1, 2008; 14(1): 17 - 28.
[Abstract] [Full Text] [PDF]


Home page
JWatch PsychiatryHome page
Negative Symptoms from Antipsychotic Medications
Journal Watch Psychiatry, April 5, 2006; 2006(405): 7 - 7.
[Full Text]




Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org